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ABSTRACT
Background: Tumorigenesis is driven by stem cell (SC) overpopulation. Because
ALDH is both a marker for SCs in many tissues and a key enzyme in retinoid acid (RA)
signaling, we studied RA signaling in normal and malignant colonic SCs.
Hypothesis: RA signaling regulates growth and differentiation of ALDH+ colonic
SCs; dysregulation of RA signaling contributes to SC overpopulation and colorectal
cancer (CRC) development.
Methods: We analyzed normal and malignant colonic tissues and CRC cell lines
to see if retinoid receptors (RXR & RAR) are exclusively expressed in ALDH+ SCs,
and if RA signaling changes during CRC development. We determined whether RA
signaling regulates cancer SC (CSC) proliferation, differentiation, sphere formation,
and population size.
Results: RXR & RAR were expressed in ALDH+ colonic SCs, but not in MCM2+
proliferative cells. Western blotting/immunostaining of CRCs revealed that RA
signaling components become overexpressed in parallel with ALDH overexpression,
which coincides with the known overpopulation of ALDH+ SCs that occurs during,
and drives, CRC development. Treatment of SCs with all-trans retinoic acid (ATRA)
decreased proliferation, sphere formation and ALDH+ SC population size, and induced
differentiation along the neuroendocrine cell (NEC) lineage.
Conclusions: Retinoid signaling, by regulating ALDH+ colonic CSCs, decreases SC
proliferation, sphere formation, and population size, and increases SC differentiation to
NECs. Dysregulation of RA signaling in colonic SCs likely contributes to overpopulation
of ALDH+ SCs and CRC growth.
Implications: That retinoid receptors RXR and RAR are selectively expressed in
ALDH+ SCs indicates RA signaling mainly occurs via ALDH+ SCs, which provides a
mechanism to selectively target CSCs.
www.oncotarget.com
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INTRODUCTION

colonic SCs and if so, how dysregulation of RA signaling
might lead to CRC progression.

Stem cell (SC) overpopulation drives colorectal
cancer (CRC) development and growth. Because
aberrant regulation of SC dynamics likely contributes to
SC overpopulation, understanding how colon SCs are
regulated is important [1]. We discovered that aldehyde
dehydrogenase (ALDH) is a marker for normal and
malignant human colon SCs and tracks SC overpopulation
during colon tumorigenesis [2]. Because ALDH is a key
enzyme in the retinoic acid (RA) signaling pathway, and
because aberrant RA signaling alters cell proliferation
and differentiation that contributes to CRC progression
[3–5], we studied RA signaling in normal and malignant
colon SCs. Our long-term goal was to determine how RA
signaling regulates SC dynamics and how dysregulation
of RA signaling leads to CRC initiation and progression.
RA signaling is mediated by two nuclear retinoic
receptor subtypes: the retinoic acid receptor (RAR) and
the retinoic X receptor (RXR) [6]. As both RXR and RAR
are involved in dimerization involving different RAR
and RXR receptor subtypes, they are the mediators of
transcriptional responses to stimuli from multiple kinds
of signaling. Both RXR and RAR receptors interact with
multiple co-activator and co-repressor proteins to promote
increased cell stemness or cell differentiation [6–9].
Two of the most common, naturally occurring
retinoic acid ligands that mediate cellular RA signaling
are all-trans retinoic acid (ATRA) and 9-cis RA [6].
These ligands are known to have different affinity for
RA receptors. Specifically, RAR subtypes have a higher
affinity to and become activated by ATRA than other RA
ligands [10, 11]. 9-cis RA binds to both RXR and RAR
receptors but with higher affinity to RXR [10]. ALDH1, a
SC marker, is a key enzyme of the RA signaling pathway
that converts retinaldehyde to ATRA, a derivative of
retinoic acid. Identifying the role of the RA signaling
pathway in colonic SCs and alterations in RA signaling in
CSCs might suggest novel targets for cancer therapeutics,
particularly since RA agents, such as ATRA, are clinically
available.
In the current study, we analyzed colon cancer
cell lines and CRC patient tumor samples to determine
if changes in key components of the RA pathway,
particularly in RXR and RAR, occur during CRC
development and progression. Other experiments were
designed to determine: 1) if RA receptors (RXR & RAR)
are selectively expressed in colonic SCs; 2) if RA signaling
regulates stemness and maturation of colonic SC, and 3)
if alterations in RA signaling occur during, and contribute
to CRC development. Because NECs mainly reside
in the crypt SC niche and can regulate the colonic SCs
characteristics [12], we also determined if there was a link
between RA receptor signaling and SC maturation toward
a neuroendocrine cell (NEC) phenotype. Our immediate
objective was to determine whether RA signaling regulates
www.oncotarget.com

RESULTS
Expression of RAR, RXR and ALDH in normal
colonic epithelium (NCE) and CRC tissues
Expression of retinoid receptors RAR and RXR was
analyzed in paraffin-embedded tissue sections of normal
colonic tissue. We found that the cells staining positively
for RAR and RXR were selectively located in the bottom
1/3 of the colonic crypts, particularly in the SC niche.
The majority of the ALDH1+ (85%), RAR+ (87%), and
RXR+ cells (63%) were located in the SC niche (crypt
levels 1-20; [2]). Co-staining for the SC marker ALDH1
and retinoid receptors showed that the majority (>90%)
of ALDH+ cells in the SC niche co-express ALDH1 with
RAR or RXR (Figure 1A). In comparison, co-staining
for ALDH and the cell proliferation marker MCM2 did
not show any overlap and the staining patterns identified
distinct cell types (Figure 1B).
To determine if expression of retinoid receptors
(RXR and RAR) becomes altered during CRC
development, immunostaining was also done on normal
colonic epithelium (NCE) and CRC tissue samples. CRC
tissue samples showed increased ALDH1, RAR, and RXR
protein expression as compared to matching normal tissues
(Figure 1C). We previously observed a similar alteration
for ALDH1 overexpression in CRC progression [2].
Given that retinoid receptors and ALDH are key
components involved in RA signaling, we also assessed
other components of the retinoid signaling pathway
using western blot analysis of matched NCE and CRC
tissue samples. In parallel with increased ALDH1, RXR
and RAR overexpression was seen in CRC as compared
to NCE (Figures 1C & 2A, 2B). CRC samples also
showed increased expression of CYP26A1 and CtBP1,
both of which are downstream of ALDH in the retinoic
acid pathway (Figure 2C). Thus we observed increased
expression of retinoid receptors, as well as of other key
components of the RA pathway in CRC tissues.

Expression of RAR, RXR, ALDH and retinoid
signaling components in CRC cell lines
To understand the relationship between ALDH1
and retinoid receptors, an in vitro tissue culture system
was employed. Based on previous screening of colon
cancer cell lines for ALDH1 expression and ALDH
activity, we chose HT29 and SW480 cells [13]. These two
cell lines were screened for protein expression of RAR,
RXR, ALDH1, CYP26A1 and CtBP1 (Figure 2A-2C).
Western blot analysis showed that both cell lines express
relatively high levels of all components of the retinoid
signaling pathway (Figure 2A-2C). Immunocytochemical
34659
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staining of HT29 and SW480 cells showed increased
RAR and RXR-alpha expression in both lines but SW480
cells had relatively more retinoid receptor positive cells
(Supplementary Figure 1).
To further analyze protein expression of RXR and
RAR in the CRC cell lines, ALDH+ cells and ALDH- cells
were sorted from the HT29 and SW480 cells using the
ALDEFLUOR assay. Western blot analysis of HT29 cells
showed increased expression of both retinoid receptors
in ALDH+ cells as compared to ALDH- cells (Figure 3).
This is not as clear in the case of SW480 cells. Even so,
we show by immunofluorescence analysis of primary
colonic tissues that there is co-staining of both RAR and
RXR with ALDH1A1 (see Figure 1).

investigated whether ATRA treatment affects sphere
formation. We surmised that if the cells are induced to
differentiate by ATRA treatment, then sphere formation
should be reduced. Indeed, HT29 cells pre-treated with
ATRA resulted in significantly fewer spheres after four
days of pre-treatment (Figure 4C). The size of the spheres
formed by HT29 cells, as measured by sphere diameter,
was not significantly altered at any time point of pretreatment (Supplementary Figure 2). ATRA pre-treatment
of SW480 cells also resulted in significantly fewer spheres
as compared to controls (Figure 4C). Similar to HT29
cells, SW480 cells formed spheres of similar size after
treatment, as compared to the controls (Supplementary
Figure 2). A representative image of the spheres formed
for both HT29 and SW480 cells are shown in Figure 4D.

Effect of ATRA on cell proliferation

Effect of ATRA on the ALDH positive SC
population size

To investigate effects of RA ligands on cell growth,
we treated colon cancer cell lines (HT29 and SW480) with
ATRA. The IC50 values were 10 μM ATRA for HT29 cells
and 100 μM ATRA for SW480 cells, as we previously
reported [14, 15].
In time course experiments, we found that cell
proliferation in both lines significantly decreased when
exposed to ATRA (Figure 4A, 4B). Thereafter, HT29
and SW480 cells were treated with the IC50 values of
ATRA in order to assess effects of RA signaling on the SC
population via the ALDEFLUOR assay, neuroendocrine
cell differentiation, and on anchorage-independent growth.

Because RA receptors appear to be selectively
expressed in ALDH+ SCs, we investigated whether the
addition of exogenous ATRA would specifically change
the ALDH+ SC population size. Both cell lines showed
a significant decrease in ALDEFLUOR+ cells. This
decrease occurred after two days of ATRA treatment of
HT29 cells (Figure 5A), and after four days of ATRA
treatment of SW480 cells (Figure 5B).

Effect of ATRA on differentiation of SCs into
NECs

Effect of ATRA on sphere formation

Because one way to characterize SCs is by their
ability to differentiate into various cell lineages, we
analyzed the effects of ATRA on differentiation into

Given these effects of RA signaling on proliferation,
SC population size and NEC differentiation, we next

Figure 1: RAR and RXR-alpha retinoid receptors co-stain with ALDH1 but not with MCM2. Normal colonic crypt

specimens from paraffin embedded tissue sections were stained which showed co-localization of retinoid receptors with the colonic SC
marker ALDH1 (Images in Panel A), but not with the proliferating cell marker MCM2 (Images in Panel B). To appreciate cell localization
of the signal, all single channels are also shown in black and white and merged channels are shown in color at higher magnification. Images
in Panel (C) show staining (red) for retinoid receptors in colon tumors compared to normal colonic epithelium.
www.oncotarget.com
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NEC cells. We did this by western blot analysis for
expression of NSE and CgA proteins, both of which are
universal markers for NECs. Our previous publication
showed that there are differential levels of expression
of NE markers between HT29 and SW480 cells, and

that is why different markers can be used to capture the
majority of NE cells in a particular cell line [12]. We also
observe, by immunofluorescence staining, co-expression
of retinoid receptors with CgA in normal colonic crypt
cells (Supplementary Figure 3) We found that ATRA

Figure 2: CRC tissue and CRC cell lines express higher levels of ALDH1 and retinoid receptors than normal colonic
tissue sections. (A) Cell lysates were collected and equal protein concentrations were run on an SDS-PAGE gel and in western blot

analyses. The representative images show increased expression of retinoid signaling pathway proteins and ALDH1 in tumor tissues and
HT29 and SW480 CRC cell lines, as compared to matched normal tissues. (B) Densitometry on western blot analysis represents the average
fold change values with increased expression of RAR in tumor tissues and CRC cell lines, as normalized to the normal colonic epithelium.
The densitometry on western blot analysis represents the average fold change values of RXR in the tumor tissues and CRC cancer cell
lines, as normalized to the normal colonic epithelium. This experiment was done in triplicate and error bars represent ± SEM, * p < 0.05.
(C) Representative western blot images show differential expression of retinoid signaling pathway proteins CtBP1 and CYP26A1, between
HT29 and SW480 cells, and these proteins are almost absent in normal colonic epithelial tissues as compared to the matched tumor tissues.

Figure 3: RAR and RXR receptor protein expression in ALDH+ and ALDH- cell populations. ALDH+ and ALDH- cells

were analyzed by the ALDEFLUOR assay and sorted as separate populations using the BD FACSAria II Flow Cytometer. Sorted cells were
pelleted and protein was extracted to run on an SDS-PAGE gel and in western blot analysis. Both RAR and RXR protein expression was
analyzed on the sorted (A) HT29 cells and (B) SW480 cells. The data represents the average densitometry values of each sample probed
for RAR or RXR and normalized to the corresponding actin. The western blot images are representative blots from one experiment done
on sorted ALDH- and ALDH+ cells from HT29 and SW480 cells and probed for RAR and RXR. Three independent sets of sorts were
performed and analyzed; error bars represent ± SEM.
www.oncotarget.com
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treatment of HT29 cells led to a significant increase in
NSE expression after 4 days of ATRA treatment (Figure
5C). SW480 cells exhibited a significant increase in CgA
expression upon ATRA treatment (Figure 5D). These
increases in ATRA-induced SC differentiation into NECs
occurred in parallel with the decrease in cell proliferation
and the decrease in size of the ALDH+ SC population.

cell proliferation for both cell lines, in a dose dependent
manner (Figure 6A). In addition, there was a decrease
in sphere formation in a dose dependent manner under
anchorage independent conditions (Figure 6B). Finally,
when HT29 and SW480 cells were treated with a low and
high concentration of CYP26A1 inhibitor, there was a
decrease in the ALDEFLUOR+ cells (Figure 6C). Overall,
the similar trends and results were seen with the addition
of exogenous ATRA and with the inhibition of CYP26A1.

Effect of CYP26A1 inhibitor liarozole
dihydrochloride on HT29 and SW480 cells

DISCUSSION

Because of the effects of ATRA on ALDEFLUOR+
cells, NEC differentiation, cell proliferation and sphere
formation, we analyzed another component of the RA
signaling pathway – CYP26A1 [16, 17]. As shown
in Figure 7, CYP26A1 is an enzyme that degrades
intracellular levels of ATRA and in cancerous cells,
CYP26A1 is significantly elevated which fools the cell
in thinking there are extremely low levels of ATRA.
In turn, the cancerous cell produces more ALDH by
increased metabolism of retinal into ATRA. Our final test
was to inhibit CYP26A1, by adding exogenous liarozole
dihydrochloride, and measure changes in ALDEFLUOR+
cells, cell proliferation, and sphere formation. After
treatment with CYP26A1 inhibitor, we saw a decrease in

A key finding is that RA signaling mainly occurs
through ALDH+ SCs. This conclusion stems from our
observation that RXR, RAR are selectively expressed in
ALDH+ SCs. For example, our analysis of colonic tissues
showed that cells staining positively for RAR and RXR
were primarily located in the SC niche at the crypt bottom,
where these cells co-stained with ALDH1. Conversely,
retinoid receptors did not co-stain with MCM2, a marker
for proliferating non-SCs. Our analysis of CRC cell lines
also shows that ALDEFLUOR+ cells, which are SCs,
tend to have higher levels of RAR and RXR. That RA
signaling mainly occurs in ALDH+ SCs, also suggests that
RA signaling regulates colonic SC dynamics.

Figure 4: ATRA treatment of both HT29 and SW480 colon cancer cell lines inhibited cell proliferation and decreased
sphere formation. (A) HT29 and (B) SW480 cells were treated with the IC50 values of ATRA over a time course and ATRA treatment
decreased cell proliferation over time. Cells were trypsinized from each well at each time point and counted using trypan blue exclusion.
Cell number at each time point was plotted on the graphs for these experiments. This experiment was done in quadruplicate and error bars
represent ± SEM, * p < 0.05. (C) Cells were serum starved for 24 hours and then treated with the IC50 value of ATRA for the designated
time points for each cell line (see Materials and Methods). Then single cells were plated for soft agar assay to measure sphere formation
after 10 days. ATRA treatment significantly decreased the number of spheres formed in HT29 and SW480 cells. (D) Representative images
of sphere formation are shown from the last time point of ATRA treatment for each cell line. The numbers of spheres were counted from
four wells of each replicate experiment. Experiments were performed in triplicate and error bars represent ±SEM, * p < 0.05. Images were
taken on a phase-contrast microscope using the brightfield setting under a 10x objective.
www.oncotarget.com
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To understand how regulation of ALDH+ SC
dynamics might occur, we considered known mechanisms
by which ALDH levels are controlled in the RA signaling
pathway (Figure 7). Specifically, ALDH expression is
regulated via a feedback mechanism involving intracellular
ATRA [18–20]. In this mechanism, an increased ATRA
concentration leads to feedback inhibition of ALDH1
expression, while decreased ALDH activity decreases
conversion of retinaldehyde to RA, which reduces the
intracellular ATRA level and lowers activation of RA
receptors. Conversely, a decreased ATRA concentration
produces the opposite response and generates positive
feedback to increase ALDH expression [18]. This feedback
mechanism also involves other components downstream
of ALDH in the RA pathway, particularly CYP26A1
and CtBP1. CYP26A1 is a cytochrome P450-associated
enzyme that metabolizes RA, breaking it down into 4-OHRA or 4-OXO-RA [16, 17]. CtBP1 is a transcriptional
corepressor which acts as a repressor of the RAR/RXR/
RARE transcriptional complex. Knowing the mechanisms
by which ALDH levels are controlled in the RA signaling
pathway, also helps us to understand how dysregulation of
the dynamics of ALDH+ SCs might occur.

Indeed, another key finding is that during CRC
development, the mechanisms that control ALDH levels
become dysregulated. For example, our immunostaining
and western blot analyses of matched NCE and CRC
tissue samples revealed that RXR and RAR become
overexpressed in parallel with increased ALDH. Our
analysis of CRC lines showed results similar to those seen
for patient tumor samples. Specifically, western blot and
immunocytochemical analysis of SW480 and HT29 cells
showed increased expression of RA receptors, RAR and
RXR, as well as increased expression of CYP26A1 and
CtBP1. That RA signaling components are overexpressed
in CRC cells and tissues suggests that dysregulation of
the mechanisms that control ALDH+ levels contributes to
overpopulation of ALDH+ CSCs in CRC.
While our results indicate that the mechanisms that
control the dynamics of ALDH+ SCs appear dysregulated
in CRC cells, we wanted to see if RA signaling is still
functional in CSCs and whether induction of RA signaling
can inhibit the growth of ALDH+ CSCs. Because
CSCs appear to contain the necessary components for
RA signaling, we determined whether RA signaling
regulates CSC phenotypes globally – at the level of cell

Figure 5: ATRA treatment of HT29 and SW480 cells decreased the percentage of ALDH+ cells and increased NSE and
CgA protein expression. (A) The HT29 cells were treated with 10 μM of ATRA and showed a significant decrease of percent ALDH+

cells at day 2. (B) The SW480 cells were treated with 100 μM of ATRA and showed a significant decrease of percent ALDH+ cells at day
4. Note: the decrease in ALDEFLUOR+ cells in DMSO controls is attributed to the decrease in proportion of ALDH+ cells that occurs due
to increased cell density of CRC cells that occurs over time in culture [13]. (C) In our studies on differentiation, HT29 cells demonstrated a
significant increase in NSE expression after 4 days of ATRA treatment. (D) SW480 cells demonstrated a significant increase in CgA at day
8 of ATRA treatment. ATRA treatment of the CRC cell lines induced neuroendocrine cell differentiation based on the protein expression
of two broad neuroendocrine markers. All western blot data (C and D) represent the average densitometry values of each sample probed
for NSE or CgA and normalized to the corresponding actin. The western blot images are representative blots from one experiment done
on HT29 and SW480 ATRA treated cells and probed for NSE and CgA. All experiments were done in triplicate and error bars represent
±SEM, * p < 0.05.
www.oncotarget.com
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Figure 6: CYP26A1 inhibitor liarozole treatment of HT29 and SW480 colon cancer cell lines decreases cell proliferation,
sphere formation and ALDH+ CSCs. (A) HT29 and SW480 cells treated with liarozole dihydrochloride inhibited cell proliferation in

a dose-dependent manner. Cells were trypsinized from each well at each time point and counted using trypan blue exclusion. The average
percent of control was plotted on the graphs for these experiments. This experiment was done in triplicate and error bars represent ± SEM,
*
p < 0.05. (B) HT29 cells were treated with liarozole dihydrochloride (0-500 μM) for three days and plated as single cells to measure
colonosphere formation. With an increase in liarozole dihydrochloride concentrations, the number of colonospheres formed decreased. This
experiment was done in triplicate and error bars represent ± SEM, * p < 0.05. Because SW480 cells demonstrate poor sphere formation, they
were not assayed. (C) HT29 and SW480 cells were treated with a low and high dose of liarozole dihydrochloride and ALDEFLUOR assay
was performed to measure changes in ALDH+ population of cells. With the high dose of liarozole dihydrochloride, there is a significant
decrease in the percent ALDH+ cells, in the SW480 cells and a decreasing trend in the HT29 cells. This experiment was done in triplicate
and error bars represent ± SEM, * p < 0.05.

Figure 7: A comparison of normal and malignant colon tissues reveals differences in the expression of several key
components in the retinoic acid (RA) signaling pathway. In the conversion of retinol to retinal a feedback regulatory mechanism
normally maintains homeostatic levels of ALDH (the enzyme that metabolizes retinal into all-trans retinoic acid - ATRA). Through this
mechanism, ALDH levels are tightly controlled by intracellular levels of retinoic acid agonists, particularly ATRA [18]. Intracellular
ATRA levels are maintained by the enzyme CYP26A1 which catalyzes ATRA degradation. Specifically, RA signaling regulates ALDH
via the binding of ATRA to retinoic acid receptors RXR and RAR that transcriptionally control ALDH gene expression. In tumor cells,
several components of this pathway are increased, including ALDH, CYP26A1 and CtBP1. Increased ALDH in tumors can be explained
by the feedback mechanism whereby increased CYP26A1 enzyme activity leads to ATRA degradation, and decreased ATRA levels then
lead to increased ALDH via feedback controls. Specifically, decreased ATRA leads to less RA signaling through RXR- and RAR-based
transcriptional control of ALDH. Moreover, we found that tumor cells have increased CtBP1, which acts as a transcriptional repressor of
the RAR/RXR/RARE transcriptional complex. Transcriptional repression by CtBP1 not only leads to increased ALDH expression, but also
up-regulates expression of genes that promote cell cycling.
www.oncotarget.com
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proliferation, CSC population size, sphere formation, and
differentiation. We did this by treating HT29 and SW480
cells with ATRA. In both time course and dose response
experiments, ATRA treatment decreased cell proliferation
of both cell lines. We also observed that ATRA
substantially decreased the proportion of ALDEFLUOR+
cells in both cell lines. This finding indicates that the
decrease in cell proliferation induced by RA signaling is
due to inhibition of growth of the ALDH+ SC population.
That ATRA induced a decrease in cell proliferation,
suggested that it was inducing differentiation. Hence,
we determined whether activation of RA receptor
signaling by ATRA induced SC differentiation toward a
NEC phenotype. We chose to specifically analyze NEC
differentiation since most crypt NECs reside adjacent to
SCs in the SC niche [12, 21]. Indeed, we observed that
differentiation toward a NEC lineage was induced in both
HT29 and SW480 cell lines upon treatment with ATRA.
The promoting effect of ATRA on NEC differentiation
in CRC cells is consistent with the fact that ATRA also
decreased ALDH+ SC population size.
Since ATRA was found to decrease SC population
size and induce differentiation, we surmised that ATRA
would also reduce SC colony growth or self-renewal.
Hence we treated SW480 and HT29 cells with ATRA
and assessed their sphere formation in soft agar assays.
Indeed, ATRA-treated HT29 and SW480 cell lines caused
a decrease in the number of spheres formed, although no
significant changes occurred in the sizes of the spheres.
Our findings that ATRA treatment decreases sphere
numbers can be explained by our results showing that
ATRA reduces ALDH+ SC population size and ATRA
increases SC differentiation, which indicates that after
being induced to differentiate by ATRA, fewer SCs exist
that can generate spheres.
Overall, we have shown that ATRA treatment affects
several CSC characteristics and functions. Specifically,
treatment of CRC cells with ATRA (i) inhibited
proliferation, (ii) decreased ALDH+ SC population size,
(iii) induced differentiation of SCs along the NEC lineage,
and (iv) reduced sphere formation. These data indicate that
RA signaling is functional in colonic CSCs and induction
of RA signaling can inhibit the growth of ALDH+ CSC
by promoting their differentiation along the NEC lineage.
Our finding that SC signaling components are
overexpressed and ALDH+ cells are overpopulated
in CRC raises the question: How do alterations in RA
signaling pathway components occur in CRC? One answer
is that it is due to mutation of the adenomatous polyposis
coli (APC) gene, which frequently occurs in CRC and is
known to drive CRC growth and development. Wildtype
APC protein is known to bind to CtBP1 and beta-catenin,
and induce degradation of both proteins. In situations
where APC is mutated, cells have impaired ability to
degrade beta-catenin, which increases TCF4 signaling
and proliferation. In the case of CRC, where APC is often
www.oncotarget.com

mutated, CtBP1 expression levels would also be predicted
to be elevated, as our results demonstrate. Overexpression
of CtBP1 has also been shown to occur in adenomas
from familial adenomatous polyposis patients who are
hereditary colon cancer patients carrying germline APC
mutations [22–24]. Thus, APC mutation likely contributes
to upregulation of at least two key components of the RA
signaling pathway.
Another question arises: How might dysregulation of
RA signaling in colonic SCs contribute to overpopulation
of colonic SCs that drives CRC development and growth.
One explanation for how ALDH becomes overexpressed
is based on changes in CYP26A1 and CtBP1 levels when
viewed in the context of the RA pathway (Figure 7). In
CRC cells, increased levels of CYP26A1 should decrease
intracellular ATRA which, via feedback regulation, would
increase ALDH expression. In fact, when a CYP26A1
inhibitor was added to HT29 and SW480 CRC cell lines,
there was a decrease in ALDEFLUOR+ cells, a decrease in
cell proliferation and decrease in sphere formation (Figure
6). Additionally, increased levels of CtBP1 will inhibit
normal cell differentiation and upregulate cell cycling
genes, which should also increase ALDH expression.
Thus, a change in the expression of key components
of the RA pathway in CRC cells likely contributes to
the overpopulation of ALDH+ SCs and diminishes cell
differentiation.
Other factors might also affect the ALDH+ SC
population size. For example, expression of different
ALDH isoforms may be a factor. Indeed, it has been
reported that specific ALDH isoforms, such as ALDH1A1,
ALDH1A2, ALDH1A3 and ALDH8A1, play a regulatory
role in the initiation and progression of CRC [25]. We
also showed that the pattern of ALDH isoform expression
changes based on CRC cell density [13]. Changes in
expression of different ALDH isoforms might influence
the ALDH+ SC population size because the various
isoforms have different substrate specificities for RA
ligands that could induce changes in RA metabolism
and affect the feedback control of ALDH levels. Thus,
in future studies, as more information becomes available
about these factors, it will be important to understand how
they relate to control of ALDH+ SCs based on the RA
signaling pathway (Figure 7).

MATERIALS AND METHODS
Immunofluorescence
Human colonic tissue sections were analyzed by
imunofluorescence as we previously described [2]. Briefly
we used anti-ALDH1 (BD Pharmingen, Franklin Lakes,
1:50), anti-RXR-alpha (Santa Cruz, 1:50), anti-RAR-alpha
(Santa Cruz, 1:50) and anti-MCM2 (Abcam, Cambridge
1:100) as primary antibodies. The use of human tissues
was approved by Institutional Review Boards of Thomas
34665
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Jefferson University and the Christiana Care Health
Services, Inc (FWA00006557).

patient consent under an approved IRB protocol. SDSPAGE was done using polyacrylamide gels (10%; Lonza)
and a Bio-rad gel electrophoresis apparatus (2 hours at
120 volts). Protein concentrations were determined using
BCA protein assay kits (Pierce, cat # 23227). Protein
was transferred to a PVDF membrane (0.45μm, Thermo
Scientific, cat # 88518). For analysis of ALDH1 (BD
Transduction Labs, cat # 611195), RXR-alpha (Abcam,
Cambridge, MA), CtBP1(Abcam), Neuron specific
enolase (NSE) (Novus Biologicals, cat# NB-110-58870)
and CgA (Abcam), membranes were blocked with 3%
BSA in Tris-Buffered Saline with 0.1% Tween 20 (TBST)
overnight at 4°C on a shaker. For CYP26A1 (Abcam)
and RAR-alpha (Santa Cruz Biotechnology Inc, Dallas,
TX) membranes were blocked with 5% milk overnight at
4°C on a shaker. Both primary and secondary antibodies
(1:20,000) were prepared in 3% BSA in TBST for
ALDH1 (1:300), RXR-alpha (1:500), CtBP1 (1:500), NSE
(1:10,000) and CgA (1:1000), and in 5% milk in TBST
for CYP26A1 (1:500) and RAR-alpha (1:800). Primary
antibody incubation was done at 4°C overnight and then
membranes were washed three times with 0.1% TBST for
10 minutes. Secondary antibody incubation was done for
1 hour at room temperature on a shaker and then washed
three times with 0.1% TBST for 10 minutes. SuperSignal
West Dura Chemiluminescent Substrate (Thermo Fisher
Scientific; cat# 34075) was used to detect horseradish
peroxidase (HRP) activity and blots were imaged using
the Syngene imaging system (Syngene, Frederick, MD).
Densitometry was done using the GeneTools software
(Syngene).

Cell culture
HT29 cells obtained from the American Type
Culture Collection (ATCC; Manassas, VA) were grown in
monolayer cultures and maintained in McCoys medium
(GIBCO/Life Technologies) supplemented with 5% fetal
bovine serum (FBS), 100 units/mL penicillin and 100μg/
mL streptomycin (P/S). SW480 cells obtained from
ATCC were maintained in Leibovitz’s 15 (L-15) medium
(GIBCO/Life Technologies) supplemented with 5%
FBS and Penicillin/Streptomycin. All cell cultures were
maintained at 37°C in humidified air at 5% CO2. Culture
medium for all cell lines was changed every 48 hours.
The cell lines were routinely tested for mycoplasma using
a Universal mycoplasma detection kit (ATCC), and all
experiments were carried out with cells cultured within
eight - ten passages before earlier freeze down were
brought up and used in additional experiments.

Immunocytochemistry (ICC)
ICC was done using SW480 and HT29 cells
between passages 6-10. ICC was done in 8-well chamber
slides from Lab tek II. SW480 and HT29 cells were fixed
with 4% paraformaldehyde for 40 minutes and then, based
on the antibody used the protocol changed. For ALDH1,
the cells were then blocked with 1% BSA, 10% serum,
0.2% triton and PBS. For RXR alpha and RAR alpha,
0.2% triton extraction for 20 minutes was done first and
the cells were then blocked with 1% BSA, 10% BSA and
PBS. Blocking was done overnight at 4 degrees, followed
by overnight primary antibody incubation at 4 degrees.
Primary antibody was washed off using blocking buffer
three times for 10 minutes each time. Secondary antibody,
Alexa flour goat anti-rabbit, was used at a dilution of
1:1000 and incubated at room temperature for 1.5 hours.
After incubation with secondary antibodies, three washes
were done with blocking buffer for 10 minutes. Cells were
dried and later stained with SlowFade® Gold antifade
DAPI and sealed with coverslips.

ALDEFLUOR assay
Theprotocol followed the manufacturer instructions
(STEMCELL Technologies, Vancouver, BC, CANADA)
with previously described modifications [12, 13]. Briefly,
cells were grown to 80% confluence and detached using
0.25% Trypsin-EDTA (Fisher Scientific). Cells were
incubated for 40 minutes at 37°C with ALDEFLUOR
reagent. Cell were resuspended in 500 μL ALDEFLUOR
buffer and transferred to a BD round bottom tube using a
50 μm cell strainer (BD Biosciences) and analyzed on a
BD FACSAria II Flow Cytometer.

Protein extraction and western blots

Cell proliferation

Cells were trypsinized, pelleted and lysed with
RIPA buffer (0.1% triton, 0.5% sodium deoxycholate,
0.1% SDS, 50 mM Tris HCl and 150 mM NaCl). Protease
inhibitor was added to the RIPA buffer just before protein
extraction. Cells were then vortexed to break up the
pellet and incubated on ice for 30 minutes. Western blot
analysis was done for HT29 cells, SW480 cells, and three
matched (patient normal and patient tumor) pairs of tissues
samples. Normal human colon samples and carcinoma
samples were obtained from Christiana Care Hospital after
www.oncotarget.com

All cells were plated at a concentration of 20,000
cells/well of a 24 well plate (four wells per cell line).
Medium was replaced every other day. Cells were detached
using 0.25% Trypsin-EDTA (Life Technologies) at days
1, 3 and 5, and counted manually with a hemocytometer.
Cells were mixed in a 1:1 ratio with Trypan blue (Fisher
Scientific) so reported cell counts include the total cell
numbers. This was repeated three times and average
values were graphed.
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Time course for ATRA

nuclear acid stain called Syto13 (Life Technologies,
Carlsbad, CA cat # S7575).

SW480 and HT29 cells were plated at 100,000 cells/
well of a 6 well tissue culture plate. Cells were incubated
for 24 hours to allow attachment and then serum starved
for 24 hours. At the time of treatment, cells were 40-50%
confluent. SW480 cells were treated with 100 μM ATRA
and HT29 cells were treated with 10 μM ATRA. The IC50
values used for these experiments have been published
by our lab previously [14, 15]. These concentrations
were determined from the dose response curves for each
cell line for each drug. SW480 and HT29 cells were
treated for the specified number of days given in results.
DMSO (0.1%) was used as a vehicle control for ATRAtreated cells. Cells were counted at each time using a
hemacytometer and trypan blue exclusion. Medium with
ATRA was changed every 2 days. Each experiment had
three replicates of drug treatment and three of vehicle. The
final time course graph was plotted based on the average
of three individual experimental sets.

Colonosphere assay
This assay was done according to our previously
published protocol [12]. Basically, untreated and liarozole
dihydrochloride treated HT29 cells were plated at a cell
density of 200 cells/100μl of sphere formation medium
and allowed to grow for 14 days. The total number of
spheres per well were counted and the average numbers
are presented in the graph.

Statistical analysis
All statistics were performed using Student’s t-test
using Microsoft excel or one-way ANOVA using Graph
Pad Prism software analysis.

CONCLUSIONS

Dose curve for liarozole dihydrochloride

In the quest to understand how ALDH+ SCs
become overpopulated in cancer, this is among the first
reports looking at the relationship between ALDH+
colonic SCs and retinoid receptors – RAR and RXR –
and the co-localization of the receptors with ALDH. In
conclusion, our results indicate that RA signaling regulates
the dynamics of colonic CSCs and dysregulation of RA
signaling contributes to CRC development. Thus, RA
signaling offers a potential therapeutic target by inducing
increased differentiation and apoptosis of colonic CSCs.
This approach would employ RA agents that restore
normal tissue homeostasis rather than trying to induce
cytotoxicity as occurs with conventional systemic anticancer treatments. Indeed, ATRA has been used as a
differentiation agent for in vitro studies and for clinical
cancer therapy [26–29]. For example, in breast cancer, it
has been shown that ATRA induced cell differentiation
in breast cancer cells and sensitized the ALDH+ breast
cancer cells to chemotherapeutics [30–33]. In acute
promyelocytic leukemia, RA agents are highly efficacious
and even curative [34]. Our findings – that RA signaling
acts through ALDH+ colonic CSCs and that ATRA
can decrease SC numbers and sphere formation via
differentiation – may provide clues as to how RA agents
in combination with other SC-targeting therapies may
be developed into new more effective approaches to the
treatment of advanced CRC.

SW480 and HT29 cells were plated at 100,000 cells/
well of a 6-well tissue culture plate. Cells were incubated
for 24 hours to allow attachment and them serum starved
for 24 hours. At the time of treatment, cells were 40-50%
confluent. HT29 and SW480 cells were treated with either
vehicle control (distilled water – 0 μM), or CYP26A1
inhibitor (Liarozole 1μM, 10μM, 50μM, 100μM, 500μM)
for 72 hours [16, 17]. Cells were trypsinized and counted
at each concentration, using a hemocytometer and trypan
blue exclusion. Experiments were done in quadruplicate
and all p-values were determined as a percent of control
(treated cells vs untreated cells (vehicle control)).

Soft agar assay for spherogenic potential
This assay was performed as we previously
published [15]. Briefly, low-melting agar (2%) and
McCoys medium containing 10% FBS (v/v), 100 U/ml
penicillin (P) and 100μg/ml streptomycin (S) in 10 mM
citrate buffer were mixed in a 1:1 volume ratio, yielding
a final concentration of 1% agar-media solution. This
solution was poured into each well of a 24 well plate
(Griener, Monroe, NC) and allowed to solidify. A second
layer containing 0.25% agar in McCoys medium with
5,000 ATRA treated HT29 cells / well was poured over
the first layer of agar and allowed to solidify. When the
second layer had solidified, McCoys medium was added
to each well. For ATRA treated SW480 cells, the same
procedure was followed as with the HT29 cells except
for the use of L15 medium. Medium was changed every
two days and cultures were allowed to grow for two
weeks before being fixed and visualized on either a phase
microscope if stained with 0.05% crystal violet or a
fluorescent microscope if stained with a green fluorescent
www.oncotarget.com

Abbreviations
ALDH: Aldehyde dehydrogenase; ATRA: all-trans
retinoic acid; CgA: Chromogranin A; CRC: colorectal
cancer; CSC: cancer stem cell; NCE: normal colonic
epithelium; NE: neuroendocrine; NSE: neuron specific
enolase; RA: retinoic acid; RAR: retinoic acid receptor;
RXR: retinoic X receptor.
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